Wegovy vs Zepbound Side-Effect Profile: A Head-to-Head Comparison

Why Comparing Side Effects Across Trials Is Complicated

Both Wegovy and Zepbound were studied in large, randomized, placebo-controlled trials, but they were never tested against each other in a single study designed to compare safety. Cross-trial comparisons carry well-known limitations: different patient populations, different titration timelines, and different reporting standards can skew any side-by-side reading.

STEP-1 enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and ran for 68 weeks 1. SURMOUNT-1 enrolled 2,539 adults with BMI ≥30 (or ≥27 with at least one comorbidity, excluding diabetes) over 72 weeks 2. The SURMOUNT-1 population was slightly larger and tested three tirzepatide doses (5 mg, 10 mg, 15 mg), while STEP-1 tested a single semaglutide dose of 2.4 mg.

The American Gastroenterological Association's 2024 clinical practice update on GLP-1 receptor agonist-associated GI adverse events noted that "gastrointestinal symptoms are the most common reason patients discontinue GLP-1-based therapies, though most events are mild to moderate and transient" 3. That observation holds true across both drugs. Given these caveats, the comparison below synthesizes published data without treating it as equivalent to a randomized head-to-head trial.

Gastrointestinal Side Effects: The Primary Concern

GI events dominate the side-effect profile for both medications. This is expected. Both drugs slow gastric emptying and act on central appetite-regulating pathways, producing nausea, vomiting, diarrhea, and constipation as dose-dependent effects.

In STEP-1, nausea occurred in 44.2% of the semaglutide 2.4 mg group versus 17.4% of placebo. Diarrhea hit 30.0% vs 15.6%, vomiting 24.8% vs 6.4%, and constipation 24.2% vs 11.1% 1. Most events were classified as mild to moderate in severity, with the highest incidence during the dose-escalation phase (weeks 1-16).

In SURMOUNT-1, nausea rates across the three tirzepatide doses were 24.6% (5 mg), 33.3% (10 mg), and 31.0% (15 mg) vs 9.5% for placebo. Diarrhea occurred in 18.7-21.2% of tirzepatide-treated participants vs 8.9% placebo. Vomiting ranged from 5.7% to 12.2% across dose tiers vs 2.8% placebo 2.

A simple cross-trial reading suggests semaglutide produced somewhat higher nausea and vomiting rates. But this comparison must be interpreted cautiously. STEP-1 used a single maximum dose, while SURMOUNT-1 spread participants across three doses. The 15 mg tirzepatide arm, which produced the greatest weight loss, reported vomiting in 12.2% of participants. That is about half the rate seen with semaglutide 2.4 mg, but the trials defined and captured adverse events using different protocols.

Discontinuation Rates Due to Adverse Events

The percentage of participants who stopped treatment because of side effects provides a practical measure of real-world tolerability, since it captures the events severe enough to end therapy.

In STEP-1 to 7.0% of participants in the semaglutide group discontinued due to adverse events, compared to 3.1% in the placebo arm. GI-specific discontinuations accounted for 4.5% of the semaglutide group 1. In SURMOUNT-1, discontinuation rates due to adverse events were 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) for tirzepatide, vs 2.6% for placebo 2.

These numbers land in a similar range. At the highest tirzepatide dose, 6.2% left the trial due to side effects, while 7.0% did so on semaglutide 2.4 mg. Neither drug shows a clear tolerability advantage based on discontinuation data alone. The clinical implication is straightforward: roughly 1 in 15 to 1 in 14 patients on either medication will find the side effects intolerable enough to stop treatment during the first year.

A 2023 meta-analysis published in JAMA Network Open that pooled data from multiple GLP-1 RA and GIP/GLP-1 RA trials confirmed that tirzepatide and semaglutide had "similar overall adverse event profiles, with gastrointestinal events as the most frequent treatment-emergent adverse events for both agents" 4.

Serious Adverse Events

Serious adverse events (SAEs) occurred in 9.8% of the semaglutide 2.4 mg group vs 6.4% in placebo in STEP-1 1. In SURMOUNT-1, SAEs were reported in 5.0% (5 mg), 6.8% (10 mg), and 7.1% (15 mg) of tirzepatide-treated participants vs 6.0% in placebo 2.

The semaglutide group's 9.8% SAE rate looks numerically higher, but the types of SAEs varied and were not concentrated in any single organ system. Pancreatitis, a theoretical concern with incretin-based therapies, occurred at very low rates in both trials. Cholelithiasis (gallstones) was reported more often in active-treatment arms of both studies, consistent with rapid weight loss rather than a direct drug effect.

The FDA prescribing information for Wegovy includes warnings for thyroid C-cell tumors (based on rodent studies), pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia (in patients on insulin or sulfonylureas), suicidal behavior and ideation, and diabetic retinopathy complications 5. The FDA label for Zepbound carries the same thyroid C-cell tumor boxed warning, plus pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury, and hypersensitivity reactions 6.

Both labels share the same boxed warning about medullary thyroid carcinoma risk, which is a class effect seen in all GLP-1 receptor agonists in rodent models. No confirmed cases of medullary thyroid carcinoma have been attributed to either drug in human trials.

Dose Titration and Its Effect on Tolerability

Slow titration is the single most effective tool for managing GI side effects with either medication. Both drugs require weeks of gradual dose increases.

Wegovy starts at 0.25 mg weekly and steps up every four weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg. The full escalation takes 16 weeks 5. Zepbound starts at 2.5 mg weekly, increases to 5 mg after four weeks, then to 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with each increase occurring at minimum four-week intervals. Full escalation to the 15 mg maximum can take 20 weeks or longer 6.

The longer titration window for tirzepatide may partially explain the lower peak nausea rates observed in SURMOUNT-1. More gradual exposure allows GI receptor desensitization to keep pace with rising drug levels. In clinical practice, some prescribers extend titration intervals for either drug when patients experience persistent nausea, which can improve adherence at the cost of delayed weight loss.

An Endocrine Society clinical practice guideline on pharmacological management of obesity (2024) recommended that clinicians "consider slowing dose titration or holding the current dose when gastrointestinal adverse effects are severe, rather than discontinuing therapy" 7.

The Weight Loss vs Side-Effect Tradeoff

Zepbound produced greater mean weight loss in its key trial: 20.9% at the 15 mg dose in SURMOUNT-1, compared to 14.9% with Wegovy 2.4 mg in STEP-1 1 2. The six-percentage-point difference is clinically meaningful.

Whether that extra efficacy comes with proportionally more side effects is the question patients care about most. The cross-trial data suggest it does not. Tirzepatide's dual mechanism (activating both GIP and GLP-1 receptors) may contribute to its enhanced efficacy without a proportional increase in GI adverse events, possibly because GIP receptor activation partially counterbalances GLP-1-mediated nausea. Preclinical data published in Cell Metabolism showed that GIP receptor co-agonism attenuated GLP-1-induced nausea signals in animal models 8.

This is a favorable therapeutic index for tirzepatide, if the cross-trial signal holds in a future direct comparison. For the individual patient, the practical question remains: which drug can you tolerate long enough to reach and maintain clinically significant weight loss?

Non-GI Side Effects Worth Tracking

Beyond the GI tract, both drugs carry side-effect signals that merit monitoring.

Injection-site reactions were reported in 3.2% of semaglutide-treated participants in STEP-1 and ranged from 2.9% to 7.3% across tirzepatide doses in SURMOUNT-1 1 2. These reactions (redness, itching, or swelling at the injection site) were mild in nearly all cases. However, tirzepatide's higher rates of injection-site events have been noted across multiple trials and may relate to the formulation or injection volume.

Heart rate increases of 1-4 beats per minute occurred with both drugs. Neither trial flagged clinically significant arrhythmias. The SELECT trial (semaglutide 2.4 mg in patients with established cardiovascular disease and obesity, published in NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events, establishing cardiovascular benefit for semaglutide 9. A dedicated cardiovascular outcomes trial for tirzepatide (SURPASS-CVOT) is still in progress; results are expected in 2027.

Hair loss (alopecia) was reported anecdotally with both medications and is a known consequence of rapid weight loss rather than a pharmacological effect. Neither trial reported statistically significant differences in hair loss between active treatment and placebo groups.

Psychiatric effects are monitored for all GLP-1 receptor agonists following FDA guidance. Post-marketing surveillance has not established a causal link between either drug and suicidal ideation, but both labels include this as a precaution. The FDA safety communication from January 2024 stated that a preliminary review of clinical trial data "did not find evidence that use of these medicines causes suicidal thoughts or actions" 10.

What a Future Head-to-Head Trial Could Settle

The SURMOUNT-5 trial (NCT06373380) is a direct comparison of tirzepatide 15 mg vs semaglutide 2.4 mg for weight management, with results expected in 2025-2026. Early topline data released by Eli Lilly in December 2024 showed that tirzepatide achieved statistically superior weight loss versus semaglutide, but full safety data have not yet been peer-reviewed and published 11.

Until the complete SURMOUNT-5 safety data are available, clinicians must rely on indirect comparisons. The Endocrine Society's 2024 guideline acknowledged that "selection among available anti-obesity medications should be individualized based on patient comorbidities, contraindications, side-effect tolerance, cost, and insurance coverage" 7. That guidance stands as the most clinically sound approach.

Practical Considerations for Patients Choosing Between the Two

Cost, insurance coverage, and supply availability all influence which drug a patient can actually access, but focusing strictly on side effects, several practical points emerge.

Patients with a history of gastroparesis or severe GERD may be more sensitive to the GI effects of either drug. Starting with the lower end of the titration schedule and extending each dose step can help. Neither drug has been shown to be safer in this population based on published evidence.

For patients already on Wegovy who are considering Zepbound (or vice versa), the transition should be managed by a prescriber familiar with both drugs. Overlapping titration periods are not recommended. A washout period is typically unnecessary given the weekly dosing schedule, but restarting titration from the lowest dose of the new drug is standard practice.

Both drugs interact with oral medications that depend on gastric emptying for absorption. The Wegovy label specifically notes that "semaglutide causes a delay in gastric emptying and has the potential to impact absorption of concomitantly administered oral medications" 5. Patients on oral contraceptives or levothyroxine should discuss timing adjustments with their prescriber.

Based on the available evidence, neither Wegovy nor Zepbound carries a clearly worse side-effect profile. The GI events are comparable in type and frequency. The choice between them should rest on efficacy goals, cardiovascular history (where semaglutide has SELECT trial data), insurance formulary placement, and individual GI tolerance during titration.